Company: HROW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001641172-25-000925
Chunk: 2435

Company: HARROW, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1C
Chunk 2435
---
 

Tax Expense

During the years ended December
31, 2024 and 2023, we recorded income tax expense of $161,000 and $701,000, respectively.

The following table presents
our net loss for the years ended December 31, 2024 and 2023:

    For the Years Ended December 31, 

    2024  
    2023 
  
    Net loss 
    $(17,481,000) 
    $(24,411,000)
  
    Net loss per share, basic and diluted 
    $(0.49) 
    $(0.75)

Liquidity and Capital Resources

Liquidity

Our cash on hand at December
31, 2024 was $47,247,000, compared to $74,085,000 at December 31, 2023.

As of the date of this Annual
Report, we believe that cash and cash equivalents of $47,247,000 at December 31, 2024 will be sufficient to sustain our planned level
of operations and capital expenditures for at least the next 12 months. Management expects to refinance the Oaktree Loan during 2025.
Management believes it is probable that we will be able to refinance the Oaktree Loan; however, there can be no assurance that we will
obtain the refinancing on terms acceptable to us, or at all - see the subheading Sources of Capital below for additional discussion
regarding the Oaktree Loan and refinancing plans. In addition, we may consider the sale of certain assets including, but not limited
to, part of, or all of, our investments in Surface and Melt and any of our consolidated subsidiaries. However, we may pursue acquisitions
of products, drug candidates or other strategic transactions that involve large expenditures or we may experience growth more rapidly
or on a larger scale than we expect, any of which could result in the depletion of capital resources more rapidly than anticipated and
could require us to seek additional financing to support our operations.

We expect to use our current
cash position and funds generated from our operations and any financing to pursue our business plan, which includes developing and commercializing
products, drug candidates, compounded formulations and technologies, integrating and developing our operations, pursuing potential future
strategic transactions as opportunities arise, including potential acquisitions of additional drug products, drug candidates, and/or
assets or technologies, pharmacies, outsourcing facilities, drug company and manufacturers, and otherwise fund our operations